Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ahfam
Good too see you back.
After difficulty comes ease.
KR
ZA
Welcome back champ, good to see you posting again x
Aye, better than before- not gone anywhere still reading and watching waiting for the consolidation, insti investments and the inevitable re-rates.
Tenantry - there has been discussion previously here of MM’s ‘borrowing’ our shares to cover trades elsewhere or something like that. Some said it’s true, others said it didn’t happen. The 1 minute it takes me to stop them being borrowed (if it happens) for 2 or 3 months is worth doing IMO. I renewed my limit order at 60p a share. They can have all mine if it rockets for £2,460,000, not a penny less.
I’ll review my price in 3 months. Many newcomers may scoff. I bet our hardened price experts like T2 and RMM would say if all ones to fruition, I sold out cheap.
Sorry but a comment by SOG regarding not making shares available has raised a question.
"SOG’s comment on not many shares in free float reminded me to lock mine in. Unsure if it’s true that they borrow them or not, but doesn’t hurt to squeeze them as much as possible. My 4.1m shares now unavailable to them. 60p, not being greedy"
What does this relate to?
Yes good to see you back Afham, would be good to know AndymkDon and Philboro are still around as long time no hear from them.
GLA
Afham...
Glad to see you back Achim, and a great post thank you
Very happy with your return Afham. Hoping you are well. GLA
Good afternoon Ahfam, I hope you are bearing up well mate, good to see you back.
ATB
Whilst covid is a nice sideplay to have we.
A timely reminder of this WHO article which was published mid-July after our Covid research update which showed we are superior to dex but we are also to bari (as bari has tox issues) both esp. Dex labelled lifesavers.
We also indicated going for bacterial pneumonia which the latest patent some think secret is targeting meaning all respiratory illnesses. We then got further £2m investment courtesy of 2 new HNWI's no co-incidence I believe.
https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access
This is from the US Army update last July -
'Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus'.
Remember 1802 is our cancer compound again has no tox or mtd but most importantly is worldwide patent protected with a new patent also applied- so it inhibits IL-6 like 1801 and also we know that 1802 has no competition in the cancer immuno market space and is almost ph1 ready.
Many happy returns chaps.
Great posts guys, especially SadOldGits thread starter, and T2’s reminder of covid being a side play.
SOG’s comment on not many shares in free float reminded me to lock mine in. Unsure if it’s true that they borrow them or not, but doesn’t hurt to squeeze them as much as possible. My 4.1m shares now unavailable to them. 60p, not being greedy
Let's not get carried away keep our feet firmly on the grounds
T2,
Many thanks for the great post.
Effectively I do not believe there are many shares in free float. 1,000,000 share buy and effectively a 10% increase. Sells shown as greater than buys. Jeez. Mind boggles if were to hit a buying frenzy on positive RNS.
Cup of tea and back to housework.
The Brucie Bonus not in the 84p is Covid 19.
The vaccines are not catching up with the rate of mutation (because the virus can incubate and mutate in ways previos pandemics cant. In people on immunosupressant drugs, and uniquely humans transmit it to animals and back again.
And as predicted will go on longer.
Prime treatments have been monoclonal antibodies. half have been banned for use by the FDA this week as innefective, plus you need a hdrip, a hospital bed, and 3 nurses per 24 hours to monitor the patient. aint got the beds or the nurses.
Remdesiver the main other treatment. The research papers say not really effective. but its clocking up sales of $4bn this year just in american hospitals.
IF and its a big IF we get funding and fast tracked to get to market asap. Thats $4bn plus for us.
last 2 years have seen bio deals at a minimum to 10* sales. Max 17* sales. That would be $40Bn mcap.
Whilst it is a side play. IF it comes off it dwarves our other value creators both in size, and time to market.
GLA. Patience pays off sometimes
I think the spike to 9p last year should be viewed just as that with hindsight. A spike. SAR currently has a market cap of 140 million which for a company still waiting for first revenue is a pretty amazing value based on IP and potential. If profit from royalties on 737 are indeed 2.7 million then on a PE of 20 that gives you 54 million value. To justify a value of 140 million at a PE of 20 you are looking for profits of 7 million a year. Of course the pipeline of products is worth a lot more than that if it all comes to fruition but we will just have wait patiently.
Last year SAR had high net worth investor buying at a much, much higher price (see below from RNS) - since then SAR has picked up fancy new broker, is pushing product into Covid development and now Sierra is falling into place. And never mind a growing bullishness for their specific area of science and research....and we're still on a low despite today's rise.
"Cambridge, UK, 9 August 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that it has raised £1,000,000, before expenses, through a subscription by a high net worth individual (the "Subscriber") for 12,121,212 new ordinary shares of 0.025p each in the capital of the Company ("Ordinary Shares") (the "Subscription Shares") at a price of 8.25p per share (the "Subscription Price") (the "Subscription")."
Sog,
Many thanks for the very informative post with real number. This number really backs up the SAR SP. So we need to hold tight and get over the bumpy ride caused by our good advisor PH.
1 million delayed buy @ 9.42 am of 1million shares for 4.425 certainly helped.
KR
ZA
Purchased some more shares first thing this morning. Surprised to see the volume of sells going though - if in fact they are sells.
Cant beat Suffolk.. we're in Long Melford..
Good morning everyone.
Nice to see some blue for a change.
Good news from over the water. Has yet to be realised over here fully. Indications are that it will be all go ahead for CHK1 development, subject to further raising by Sierra.
Should give us milestone payment by mid year of half a million with milestones later to follow. SRA 737 coming to fruition.
Not sure how PH will keep the price supressed as done their best so far.
News awaits us on toxicity reports. Should be all thumbs up here. Tim is confident and indeed is clearly excited by the prospect.
Positive news on CHK1 development along with good toxicology report will propel us upwards.
Will address the 3 billion as mentioned earlier but this was the figure for Addressable Market for Momo in US alone. Chk1 would have a lot wider figure especially world wide.
Once into the market we would have received circa 70 million milestone payments ie 27.5% of 290 million dollars.
Royalties would be 27.5% of a Royalty payment in total of net profit. Figure here was expected around the 10% from memory.
if we use the figure of 200 million dollars a year and profit margin around 50% that would give us 2.7% of 100 million. This circa 2.7 million a year.
This is a pessimistic turnover. But most important of all it gives Sareum a steady stream of income. No more doubt as to the liquidity of the company.
I will do some more looking into when have time. Had a long 14 hr, 702 mile drive from Thurso to back home in Suffolk on Monday. Slept well last night.
Regards